Heparin and antiaggregating therapy in unstable angina

G. G. Neri Serneri, P. A. Modesti, R. Abbate, G. F. Gensini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Heparin and antiaggregating therapy represent an effective treatment of unstable angina. Aspirin is able to prevent myocardial infarction and death in patients with unstable angina, but is not able to control myocardial ischemia. On the contrary, heparin administered by continuous intravenous infusion (about 1,000 U/h) controls myocardial ischemia by very early lowering anginal attacks and silent ischemic episodes. Heparin intermittently administered (6,000 U i.v. four times daily) did not significantly affect anginal attacks and myocardial ischemia. Thrombolytic therapy alone (Alteplase 1.75 mg/kg) reduced, but not significantly, the number of anginal attacks. The reduction of myocardial ischemia induced by continuous infusion of heparin is associated with a decrease of fibrinopeptide A plasma levels, whereas the thromboxane B2 production by platelets seems to be irrelevant in order to obtain a reduction of myocardial ischemia. Thus thrombin formation seems to be a primary factor in the occurrence of refractory unstable angina and in the activation of platelets.

Original languageEnglish
Pages (from-to)113-121
Number of pages9
JournalHaemostasis
Volume20
Issue numberSUPPL. 1
Publication statusPublished - 1990

Fingerprint

Unstable Angina
Myocardial Ischemia
Heparin
Fibrinopeptide A
Therapeutics
Thromboxane B2
Thrombolytic Therapy
Platelet Activation
Tissue Plasminogen Activator
Intravenous Infusions
Thrombin
Aspirin
Blood Platelets
Myocardial Infarction

Keywords

  • heparin
  • myocardial ischemia
  • unstable angina

ASJC Scopus subject areas

  • Hematology

Cite this

Neri Serneri, G. G., Modesti, P. A., Abbate, R., & Gensini, G. F. (1990). Heparin and antiaggregating therapy in unstable angina. Haemostasis, 20(SUPPL. 1), 113-121.

Heparin and antiaggregating therapy in unstable angina. / Neri Serneri, G. G.; Modesti, P. A.; Abbate, R.; Gensini, G. F.

In: Haemostasis, Vol. 20, No. SUPPL. 1, 1990, p. 113-121.

Research output: Contribution to journalArticle

Neri Serneri, GG, Modesti, PA, Abbate, R & Gensini, GF 1990, 'Heparin and antiaggregating therapy in unstable angina', Haemostasis, vol. 20, no. SUPPL. 1, pp. 113-121.
Neri Serneri GG, Modesti PA, Abbate R, Gensini GF. Heparin and antiaggregating therapy in unstable angina. Haemostasis. 1990;20(SUPPL. 1):113-121.
Neri Serneri, G. G. ; Modesti, P. A. ; Abbate, R. ; Gensini, G. F. / Heparin and antiaggregating therapy in unstable angina. In: Haemostasis. 1990 ; Vol. 20, No. SUPPL. 1. pp. 113-121.
@article{e4cd846ff1374d8d80b337f973c43200,
title = "Heparin and antiaggregating therapy in unstable angina",
abstract = "Heparin and antiaggregating therapy represent an effective treatment of unstable angina. Aspirin is able to prevent myocardial infarction and death in patients with unstable angina, but is not able to control myocardial ischemia. On the contrary, heparin administered by continuous intravenous infusion (about 1,000 U/h) controls myocardial ischemia by very early lowering anginal attacks and silent ischemic episodes. Heparin intermittently administered (6,000 U i.v. four times daily) did not significantly affect anginal attacks and myocardial ischemia. Thrombolytic therapy alone (Alteplase 1.75 mg/kg) reduced, but not significantly, the number of anginal attacks. The reduction of myocardial ischemia induced by continuous infusion of heparin is associated with a decrease of fibrinopeptide A plasma levels, whereas the thromboxane B2 production by platelets seems to be irrelevant in order to obtain a reduction of myocardial ischemia. Thus thrombin formation seems to be a primary factor in the occurrence of refractory unstable angina and in the activation of platelets.",
keywords = "heparin, myocardial ischemia, unstable angina",
author = "{Neri Serneri}, {G. G.} and Modesti, {P. A.} and R. Abbate and Gensini, {G. F.}",
year = "1990",
language = "English",
volume = "20",
pages = "113--121",
journal = "Haemostasis",
issn = "0301-0147",
publisher = "S. Karger AG",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Heparin and antiaggregating therapy in unstable angina

AU - Neri Serneri, G. G.

AU - Modesti, P. A.

AU - Abbate, R.

AU - Gensini, G. F.

PY - 1990

Y1 - 1990

N2 - Heparin and antiaggregating therapy represent an effective treatment of unstable angina. Aspirin is able to prevent myocardial infarction and death in patients with unstable angina, but is not able to control myocardial ischemia. On the contrary, heparin administered by continuous intravenous infusion (about 1,000 U/h) controls myocardial ischemia by very early lowering anginal attacks and silent ischemic episodes. Heparin intermittently administered (6,000 U i.v. four times daily) did not significantly affect anginal attacks and myocardial ischemia. Thrombolytic therapy alone (Alteplase 1.75 mg/kg) reduced, but not significantly, the number of anginal attacks. The reduction of myocardial ischemia induced by continuous infusion of heparin is associated with a decrease of fibrinopeptide A plasma levels, whereas the thromboxane B2 production by platelets seems to be irrelevant in order to obtain a reduction of myocardial ischemia. Thus thrombin formation seems to be a primary factor in the occurrence of refractory unstable angina and in the activation of platelets.

AB - Heparin and antiaggregating therapy represent an effective treatment of unstable angina. Aspirin is able to prevent myocardial infarction and death in patients with unstable angina, but is not able to control myocardial ischemia. On the contrary, heparin administered by continuous intravenous infusion (about 1,000 U/h) controls myocardial ischemia by very early lowering anginal attacks and silent ischemic episodes. Heparin intermittently administered (6,000 U i.v. four times daily) did not significantly affect anginal attacks and myocardial ischemia. Thrombolytic therapy alone (Alteplase 1.75 mg/kg) reduced, but not significantly, the number of anginal attacks. The reduction of myocardial ischemia induced by continuous infusion of heparin is associated with a decrease of fibrinopeptide A plasma levels, whereas the thromboxane B2 production by platelets seems to be irrelevant in order to obtain a reduction of myocardial ischemia. Thus thrombin formation seems to be a primary factor in the occurrence of refractory unstable angina and in the activation of platelets.

KW - heparin

KW - myocardial ischemia

KW - unstable angina

UR - http://www.scopus.com/inward/record.url?scp=0025633151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025633151&partnerID=8YFLogxK

M3 - Article

C2 - 2083863

AN - SCOPUS:0025633151

VL - 20

SP - 113

EP - 121

JO - Haemostasis

JF - Haemostasis

SN - 0301-0147

IS - SUPPL. 1

ER -